公开(公告)号：US20180369242A1

公开(公告)日：2018-12-27

申请号：US16062399

申请日：2016-12-15

Applicant: PRECEDO PHARMACEUTICALS CO., LTD

Inventor： Jing LIU ,  Qingsong LIU ,  Taoshan JIANG ,  Aoli WANG ,  Jiaxin WU ,  Hong WU ,  Ziping QI ,  Yongfei CHEN ,  Fengming ZOU ,  Wenchao WANG ,  Zheng ZHAO ,  Li WANG ,  Beilei WANG

IPC: A61K31/506 ,  A61P35/00 ,  C07D409/12 ,  C07D401/12 ,  C07D239/47 ,  A61K31/5377 ,  A61K31/551 ,  C07D239/48 ,  C07D403/12

CPC classification number: A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  A61P35/00 ,  C07D239/47 ,  C07D239/48 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12 ,  Y02P20/55

Abstract: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.